Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating
© MT Newswires 2021
| All news about EXICURE, INC. |
|
| 05/20 | Top Premarket Gainers | MT |
| 05/19 | INSIDER BUY : Exicure | MT |
| 05/17 | Exicure, Inc. - Reports First Quarter 2022 Financial Results and Corporate Progress | AQ |
| 05/17 | Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference | BU |
| 05/16 | EXICURE, INC. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 05/16 | Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/16 | Earnings Flash (XCUR) EXICURE Reports Q1 Revenue $2.57M | MT |
| 05/16 | Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress | BU |
| 05/13 | EXICURE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Se.. | AQ |
| 05/11 | Thinking about buying stock in Exicure, Vroom, Redbox, Amyris, or Plug Power? | PR |
| |
|
| Analyst Recommendations on EXICURE, INC. |
|
| |
|
|
|
| Sales 2022 |
17,3 M
-
-
|
| Net income 2022 |
-
-
-
|
| Net Debt 2022 |
-
-
-
|
| P/E ratio 2022 |
-0,97x |
| Yield 2022 |
- |
|
| Capitalization |
17,8 M
17,8 M
-
|
| Capi. / Sales 2022 |
1,03x |
| EV / Sales 2023 |
|
| Nbr of Employees |
40 |
| Free-Float |
86,0% |
|
|
Duration :
Period :
|
Technical analysis trends EXICURE, INC.
| Short Term | Mid-Term | Long Term | | Trends | Bearish | Bearish | Bearish |
Income Statement Evolution
|
| Mean consensus |
HOLD |
| Number of Analysts |
1 |
| Last Close Price |
0,15 $ |
| Average target price |
0,25 $ |
| Spread / Average Target |
72,4% |
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
